Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 5,572 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Degenerative Conditions, Neurologic Clear all

Conditions: Myasthenia Gravis
Interventions: ME&MGopen smartphone application; Device
Lead sponsor: Ad scientiam; Other
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alzheimer Disease
Interventions: F 18 T807 Flortaucipir; Drug
Lead sponsor: Tammie L. S. Benzinger, MD, PhD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer's Disease
Interventions: Home-Based Behavorial Intervention; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dysautonomia, Familial, Baroreflex Failure Syndrome
Interventions: Carbidopa Low-Dose, Placebo, Carbidopa High-Dose; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 10 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Mild Cognitive Impairment (MCI), Parkinsons Disease (PD), Healthy Adult
Interventions: transcutaneous auricular vagus nerve stimulation, sham stimulation; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Alzheimer Disease, Cognitive Impairment
Interventions: Routine care, Coaching plus routine care; Behavioral · Other
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 50 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Interventions: SF1126; Drug
Lead sponsor: Ezra Cohen; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Amyloidosis
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 14
States / cities: La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more

Conditions: Alzheimer Disease, Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID), Mixed Etiology Dementias (MED), Mild Cognitive Impairment (MCI)
Interventions: Problem Solving Training; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: College Station, Texas • Dallas, Texas • Edinburg, Texas

Conditions: Neurofibromatosis 1, Malignant Peripheral Nerve Sheath Tumor (MPNST) of Soft Tissue (Diagnosis), Atypical Neurofibroma
Interventions: Whole Body Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vascular Anomalies, Vascular Anomaly, TIE2/PIK3CA Pathway Driven Vascular Anomalies
Interventions: alpelisib (BYL719); Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 30 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders, Circadian Dysregulation
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Traumatic Brain Injury, Post Traumatic Stress Disorder, Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 50 Years to 90 Years
Enrollment: 289 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 19
States / cities: Sun City, Arizona • Irvine, California • La Jolla, California + 14 more

Conditions: Spinal Muscular Atrophy
Interventions: Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Months to 60 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 4
States / cities: Palo Alto, California • Orlando, Florida • Boston, Massachusetts + 1 more

Conditions: Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy, Hemiplegia, Hemiparesis, Multiple Sclerosis, Parkinson Disease, Trauma, Brain, Transverse Myelitis, Friedreich Ataxia
Interventions: Seated exercise; Behavioral
Lead sponsor: Burke Medical Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Parkinson's Disease
Interventions: DNS-7801 (low-dose), DNS-7801 (high dose), Placebo; Drug
Lead sponsor: Dart NeuroScience, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 9
States / cities: Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more

Conditions: Parkinson Disease
Interventions: Clarithromycin (Not used as of 4/2020), Placebo (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020), Placebo (Added 4/2020); Drug
Lead sponsor: Nicolaas Bohnen, MD, PhD; Other
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: The Parkinson's Institute; Other
Eligibility: Up to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Parkinson's Disease, Obsessive Compulsive Disorder, Dystonia, Essential Tremor, Epilepsy
Interventions: Stereotactic brain procedures; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 90 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Stroke, Parkinson Disease, Lower Limb Amputation Knee, Fall Injury, Fall Patients, Falling
Interventions: Airbag Belt Fall Protection System; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 55 Years and older
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2031
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2
Interventions: RNA antisense oligonucleotide for intravitreal injection; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more

Conditions: Apraxia of Speech, Non-fluent Aphasia, Primary Progressive Aphasia, Primary Progressive Nonfluent Aphasia
Interventions: Testing protocol for the study; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Parkinson Disease
Interventions: Capsaicin, Resistive respiratory loads, Event-related evoked potential using electroencephalography (EEG)., Fluoroscopic swallow evaluation; Drug · Device · Other + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 85 Years
Enrollment: 119 participants
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Descriptive Analysis of Real-world Data Collected with ME&MGopen

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.

Project TAP: Tailored Activities Project

Carbidopa for the Treatment of Excessive Blood Pressure Variability

Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations

Coaching for Cognition in Alzheimer's (COCOA)

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia

Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1

24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon

A Study of Brain Aging in Vietnam War Veterans

A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

Home Based Tele-exercise for People With Chronic Neurological Impairments

DNS-7801 vs. Placebo in Parkinson's Disease

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

Physiological Brain Atlas Development

Wearable Airbag Technology to Mitigate Falls in Individuals With High Fall Risk

Wake Forest Alzheimer's Disease Clinical Core

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

Airway Protective Mechanisms in PD (R01)